Brief: Oncovent initiates clinical development program for anti-MUC1 MAb AR20.5 for treatment of pancreatic cancer02/11/2016 13:31
Brief: Quest Pharmatech says unit signs agreement with Shenzhen Hepalink Pharmaceutical to fund immunotherapy for treatment of cancer in China22/03/2016 13:30
Last trade - 00:00Last trade - 00:00Last trade - 00:00